1. EMEA (2003) Committee for Medicinal Products for Human Use. Note for guidance on evaluation of anticancer medicinal products in man—addendum on paediatric oncology; London, 24 July 2003. http://www.emea.europa.eu.int CPMP/EWP/569/02. Accessed 15 March 2010
2. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL for the Childhood Cancer Survivor Study (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355(15):1572–1582
3. Oeffinger KC, Hudson MM (2004) Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 54:208–236
4. EMEA (2006) Committee for Medicinal Products for Human Use. Guideline on clinical trials in small populations; London, 27 July 2006. http://www.emea.europa.eu.int Ref. CHMP/EWP/83561/2005. Accessed 15 March 2010
5. European Parliament and Council Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of Good Clinical Practice in conduct of clinical trials on medical products for human use. Official Journal of the European Union 1.5.2000; L 121/34